Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:1412 (17 June), doi:10.1136/bmj.332.7555.1412-a
Ray Moynihan
Byron Bay, Australia
| The first 150 words of the full text of this article appear below. |
The International Obesity Task Force has relied heavily on funding from the drug industry for a decade, despite being widely seen as an independent think tank and having ties to the World Health Organization.
Set up in the mid-1990s with help from grants from three drug companies, the task force aims to portray obesity as a "serious medical condition" and to promote better prevention and management strategies.
It has a high media profile and is highly influential. A senior US member and a well respected authority on obesity, William Dietz, is currently one of the driving forces behind a controversial change in definitions of childhood overweight and obesity, which some researchers believe may exaggerate the problem and unnecessarily label children as diseased. (See accompanying story p 1412.)
Although the task force has at times disclosed the names of drug company sponsors, the exact amount of that sponsorship remains secret.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses